The numbers are in! Each year, the employee benefits industry waits for the annual ranking of Canada’s top group benefits providers, and the 2025 figures offer another window into where the market is heading. The big names held their ground, the smaller carriers kept climbing, and the cost pressures shaping every plan in the country came into sharper focus.
Let’s dig into the numbers and what they mean for Canadian employers.
The “Big 3” Remain Firmly on Top
Canada Life leads at $15.36 billion (up 2.9%), followed by Sun Life at $13.40 billion (up 5.5%) and Manulife at $13.33 billion (up 4.8%). But the most striking story isn’t at the top; it’s the pace of growth further down the list, where Wawanesa Life jumped 19.7%, Medavie Blue Cross rose 11%, and Equitable Life climbed 9.6%. Chubb Life was the lone decliner, slipping 4.5%.
High-Cost Specialty Drugs Keep Reshaping The Math
The single biggest pressure on Canadian benefits plans isn’t a new perk or a flashy feature — it’s the cost of medication. Specialty drugs with annual treatment costs of at least $10,000 now account for roughly a third of total private drug plan spend, despite being used by only about 2% of claimants, according to TELUS Health data. Ultra-high-cost therapies — those exceeding $100,000 a year — represent a small but growing slice, and a single catastrophic claim can put real strain on a plan. For employers, this is the quiet force behind rising premiums, and it’s why plan design and pooling arrangements deserve a closer look than they used to.
Weight-Management Drugs Move From Exclusion to Mainstream
A few years ago, drugs like Ozempic and Wegovy were a standard exclusion on most private plans. That’s changing fast. The weight-management category grew 104% in 2024 and another 61% in 2025, climbing to become the 11th-largest drug category by spend, according to a TELUS Health report. With Health Canada’s 2025 approval of Zepbound and the generic Ozempic, demand isn’t slowing down. Employers now face a genuine decision: whether to cover these therapies, how to manage the cost if they do, and how to communicate that choice to a workforce that increasingly expects coverage. It’s a conversation that didn’t exist on most renewal calls a few years ago.
National Pharmacare Begins To Shift The Cost Equation
For the first time, the relationship between public and private drug coverage is meaningfully in motion. Canada’s Pharmacare Act for diabetes drugs took effect in October 2024, with Manitoba and Prince Edward Island launching programs in 2025 and British Columbia following in early 2026. As more provinces come online, private plans may see some of their exposure to high-volume categories like diabetes — currently the top drug category by spend — gradually decline. The full picture will take years to settle, but the direction is clear: the line between what the government pays for and what employer plans pay for is being redrawn, and plan sponsors will want to stay close to how it affects their costs province by province.
What This Means For Employers
The 2025 rankings tell a familiar story with a sharper edge. The market is stable at the top, competitive in the middle, and increasingly defined by forces —drug costs, new therapies, and shifting public coverage—that sit largely outside any single employer’s control. That makes plan design, carrier fit, and regular reviews more important than ever. The right provider isn’t simply the biggest one on the list; it’s the one that fits your team, your stage of growth, and your budget, and that can help you navigate a benefits landscape that clearly isn’t standing still.